Condition (MeSH)
Dysentery, Bacillary
ClinicalTrials.gov lists 61 trials for Dysentery, Bacillary or a narrower condition beneath it. LimmaTech Biologics AG has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
61 of the 61 trials are tagged with Dysentery, Bacillary itself; the rest are tagged with a narrower condition beneath it.
When did Dysentery, Bacillary trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 3 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 4 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 49 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dysentery, Bacillary trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 25 |
| Phase 1/2 | 6 |
| Phase 2 | 17 |
| Phase 3 | 5 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 5 |
How many Dysentery, Bacillary trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Completed | 44 |
| Terminated | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dysentery, Bacillary trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| LimmaTech Biologics AG | 5 |
| Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 4 |
| GlaxoSmithKline | 4 |
| U.S. Army Medical Research and Development Command | 4 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 3 |
Showing 5 of 10 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Azithromycin | 3 |
| Shigella sonnei 53G | 3 |
| S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine | 3 |
| CVD 1208S, a Shigella flexneri 2a live, oral vaccine | 2 |
| MenACWY | 2 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Dysentery, Bacillary trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 3 | 1 |
| Gastroenteritis | 2 | 1 |
| Abortion | 1 | 1 |
| Carotid artery aneurysm | 1 | 1 |
| Deep vein thrombosis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Dysentery, Bacillary? (68)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Tebipenem pivoxil as an alternative to ceftriaxone for clinically non-responding children with shigellosis: a randomised non-inferiority trial protocol. | BMJ open | 2025 | Yes |
| Dynamics of the gut microbiome in subjects challenged with <i>Shigella sonnei</i> 53G in a controlled human infection model. | mSphere | 2025 | Yes |
| Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study. | The Journal of infectious diseases | 2024 | Yes |
| Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge. | Vaccine | 2024 | Yes |
| Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023 | Yes |
Showing 5 of 68 publications.
Prevalence (30)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Shigellosis | Annual incidence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Shigellosis | Annual incidence | 1-9 / 1 000 000 | Iceland | Not stated | Unspecified |
| Shigellosis | Annual incidence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Shigellosis | Annual incidence | 1-9 / 100 000 | Netherlands | Not stated | Unspecified |
| Shigellosis | Annual incidence | 1-9 / 100 000 | Czech Republic | Not stated | Unspecified |
Showing 5 of 30 prevalence observations.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.